Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 32Tacrolimus 29fludarabine 27Mycophenolic Acid 23fludarabine phosphate 22Busulfan 19Whole-Body Irradiation 18Melphalan 16Methotrexate 15Antilymphocyte Serum 14Rituximab 12Bortezomib 11Stem Cell Transplantation 10Cyclosporine 10thymoglobulin 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Interviews as Topic 7Filgrastim 7Dexamethasone 7Clofarabine 7Blood Specimen Collection 6Alemtuzumab 6merphos 5Voriconazole 5Standard of Care 5Nivolumab 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hematologic Neoplasms × Amides × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡